Cefixime

Pharmacologic Category

Antibiotic, Cephalosporin (Third Generation)

Dosing: Adult

Usual dosage range: Oral: 400 mg daily divided every 12 to 24 hours.

Gonococcal infection, uncomplicated infections of the cervix, urethra or rectum (rectum off-label use): Oral: 400 mg as a single dose in combination with oral azithromycin as a single dose (CDC [Workowski 2015]). Note: CDC no longer recommends cefixime as a first-line agent (ceftriaxone is the preferred cephalosporin in combination with azithromycin); cefixime should only be used if ceftriaxone is unavailable. In addition, cefixime is not an option for the treatment of uncomplicated gonorrhea of the pharynx due to limited efficacy; if it must be used instead of ceftriaxone, a test-of-cure follow up should be performed 14 days after treatment (CDC [Workowski 2015]). In Canada, due to increased antimicrobial resistance, the Public Health Agency of Canada recommends 800 mg as a single dose (off-label dose) for treatment of uncomplicated gonococcal infections.

Gonococcal infection, expedited partner therapy (off-label use): Oral: 400 mg as a single dose in combination with oral azithromycin (CDC [Workowski 2015]). Note: To be used only for heterosexual partners with gonorrhea if health department partner-management strategies are impractical/unavailable and there is concern by the provider for the prompt evaluation and treatment of the partner; medication may be delivered to partner by patient, collaborating pharmacy, or disease investigation specialist as permitted by law; written materials to educate partners about their exposure to gonorrhea, importance of therapy, and when to seek clinical evaluation for adverse reactions/complications must also be provided with the medication (CDC [Workowski 2015]).

Rhinosinusitis, acute bacterial (alternative agent for penicillin-allergic patients able to tolerate cephalosporins) (off-label use): Oral: 400 mg once daily for 5 to 7 days; if concern for pneumococcal resistance, add clindamycin (IDSA [Chow 2012]; Patel 2018). Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients (AAO-HNS [Rosenfeld 2015]; Harris 2016).

Streptococcal pharyngitis (group A) (alternative agent for mild [non-anaphylactic] penicillin allergy): Oral: 400 mg once daily for 10 days (IDSA [Shulman 2012]; Pichichero 2018; manufacturer’s labeling)

Manufacturer’s labeling: Dosing in the prescribing information may not reflect current clinical practice: 200 mg twice daily

Typhoid fever (off-label use): Oral: 100 to 200 mg twice daily for 7 to 14 days (WHO 2003)

Urinary tract infection (UTI) (alternative agent): Note: Use with caution and only when recommended agents cannot be used (due to decreased efficacy of oral beta-lactams compared to other agents) (ESMID/IDSA [Gupta 2011]; Hooton 2018a).

Cystitis, acute uncomplicated: Oral: 400 mg once daily for 7 days (ESMID/IDSA [Gupta 2011]; Nicolle 2008)

UTI, complicated, including pyelonephritis: Oral: 400 mg once daily (Johnson 2018; Moustafa 2016; Sanchez 2002) for 10 to 14 days (ESMID/IDSA [Gupta 2011]; Johnson 2018). Note: Oral therapy should follow appropriate parenteral therapy. For outpatient treatment of mild infection, a single dose of a long-acting parenteral agent is acceptable (ESMID/IDSA [Gupta 2011]; Hooton 2018b).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

CrCl ≥60 mL/minute: No dosage adjustment necessary.

CrCl 21 to 59 mL/minute:

Chewable tablet: Not recommended

100 mg/5 mL, 200 mg/5 mL, or 500 mg/5 mL suspension: 260 mg once daily

CrCl ≤20 mL/minute:

Chewable tablet: 200 mg once daily

100 mg/5 mL suspension: 172 mg once daily

200 mg/5 mL suspension: 176 mg once daily

500 mg/5 mL suspension: 180 mg once daily

Intermittent hemodialysis (not significantly removed by hemodialysis):

Chewable tablet: Not recommended

Suspension: 260 mg once daily

CAPD (not significantly removed by peritoneal dialysis):

Chewable tablet: 200 mg once daily

100 mg/5 mL suspension: 172 mg once daily

200 mg/5 mL suspension: 176 mg once daily

500 mg/5 mL suspension: 180 mg once daily

Canadian labeling:

CrCl ≥40 mL/minute: No dosage adjustment necessary

CrCl 20 to <40 mL/minute: Administer 75% of normal daily dose

CrCl <20 mL/minute: Administer 50% of normal daily dose

Dosing: Hepatic Impairment: Adult

No dosage adjustment provided in manufacturer’s labeling.

Dosing: Pediatric

Note: Unless otherwise specified, any dosage form may be used.

General dosing; susceptible infection (mild to moderate): Infants, Children, and Adolescents: Oral: 8 mg/kg/day divided every 12 to 24 hours; maximum daily dose: 400 mg/day (Red Book [AAP 2015])

Febrile neutropenia (low-risk): Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours; in most trials, cefixime therapy was initiated as step-down therapy after 48 to 72 hours of empiric parenteral antibiotic therapy with first cefixime dose administered at the end of the last IV infusion (Klaassen 2000; Lehrnbecher 2017; Paganini 2000; Shenep 2001). Note: In clinical trials, doses were repeated if patient vomited within 2 hours.

Gonococcal infection, uncomplicated infections of the cervix, urethra, or rectum: Children ≥45 kg and Adolescents: Oral: 400 mg as a single dose in combination with oral azithromycin as a single dose (CDC [Workowski 2015]). Note: CDC no longer recommends cefixime as a first-line agent (ceftriaxone is the preferred cephalosporin in combination with azithromycin); cefixime should only be used if ceftriaxone is unavailable. In addition, cefixime is not an option for the treatment of uncomplicated gonorrhea of the pharynx due to limited efficacy; if it must be used instead of ceftriaxone, a test-of-cure follow up should be performed 14 days after treatment (CDC [Workowski 2015]). In Canada, due to increased antimicrobial resistance, the Public Health Agency of Canada recommends 800 mg as a single dose for treatment of uncomplicated gonococcal infections (Public Health Agency of Canada 2012).

Irinotecan-associated diarrhea, prophylaxis: Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg once daily; begin 5 days before oral irinotecan therapy and continue throughout course (Wagner 2008)

Otitis media, acute: Oral suspension or chewable tablets: Infants, Children, and Adolescents: Oral: 8 mg/kg/day divided every 12 to 24 hours; maximum daily dose: 400 mg/day

Pharyngitis or tonsillitis; S. pyogenes: Note: Not preferred for treatment in IDSA Guidelines due to unnecessary broad spectrum, and lack of selectivity for antibiotic resistant flora (IDSA [Schulman 2012]); Infants, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours for ≥10 days; maximum daily dose: 400 mg/day

Pneumonia, community-acquired (CAP); haemophilus influenza types A-F or nontypeable; mild infection or step-down therapy: Infants ≥3 months, Children, and Adolescents: Oral: 8 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 400 mg/day (IDSA/PIDS [Bradley 2011]) Red Book [AAP 2015])

Rhinosinusitis, acute bacterial: Infants, Children, and Adolescents: Oral: 4 mg/kg/dose every 12 hours with concomitant clindamycin for 10 to 14 days; maximum daily dose: 400 mg/day. Note: Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age <2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).

Typhoid fever (Salmonella typhi): Limited data available; efficacy results variable: Infants, Children and Adolescents: Oral: 7.5 to 10 mg/kg/dose every 12 hours for 7 to 14 days (Cao 1999; Girgis 1995; Stephens 2002)

Urinary tract infection; acute: Oral:

Manufacturer's labeling: Infants ≥6 months, Children, and Adolescents: 8 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 400 mg/day

Alternate dosing: Infants ≥2 months and Children ≤2 years: Initial: 8 mg/kg/day every 24 hours for 7 to 14 days; in patients <24 months, shorter courses (1 to 3 days) have been shown to be inferior to longer durations of therapy (AAP 2011)

Dosing: Renal Impairment: Pediatric

Infants ≥6 months, Children, and Adolescents: Very limited data available; some clinicians have suggested the following (Daschner 2005; Dhib 1991):

Mild to moderate impairment: No adjustment recommended

Severe impairment (eg, GFR ≤10 to 20 mL/minute/1.73 m²): Reduce dose by 50%

Anuric: Reduce dose by 50%

Hemodialysis, peritoneal dialysis: Not significantly removed

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Calculations

• Creatinine Clearance by Cockcroft-Gault
• Creatinine Clearance by Cockcroft-Gault (SI units)
• Creatinine Clearance by Cockcroft-Gault with IBW
• Creatinine Clearance by Cockcroft-Gault with IBW (SI units)
• Creatinine Clearance by Jelliffe
• Creatinine Clearance by Sanaka
• Glomerular Filtration Rate by Abbreviated MDRD
• Glomerular Filtration Rate by Abbreviated MDRD (SI units)
• Glomerular Filtration Rate by MDRD
• Glomerular Filtration Rate by MDRD (IDMS-Traceable SCr)
• Glomerular Filtration Rate by MDRD (SI units)
• Glomerular Filtration Rate Estimate in African Americans by AASK Equation

Use: Labeled Indications

Treatment of uncomplicated urinary tract infections (due to Escherichia coli and Proteus mirabilis), otitis media (due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), pharyngitis and tonsillitis (due to Streptococcus pyogenes), acute exacerbations of chronic bronchitis (due to Streptococcus pneumoniae and Haemophilus influenzae); uncomplicated cervical/urethral gonorrhea (due to N. gonorrhoeae [penicillinase- and nonpenicillinase-producing])

Note: Due to concerns of resistance, the CDC no longer recommends use of cefixime as a first-line regimen in the treatment of uncomplicated gonorrhea in the US; ceftriaxone is the preferred cephalosporin in combination with azithromycin (CDC 2012; CDC [Workowski 2015]).

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Gonococcal infection, expedited partner therapyLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, cefixime in combination with azithromycin is an effective and recommended treatment of gonorrhea only in the following circumstances: Heterosexual partners with gonorrhea if health department partner-management strategies are impractical/unavailable and there is concern by the provider for the prompt evaluation and treatment of the partner; medication may be delivered to partner by patient, collaborating pharmacy, or disease investigation specialist as permitted by law; written materials to educate partners about their exposure to gonorrhea, importance of therapy, and when to seek clinical evaluation for adverse reactions/complications must also be provided with the medication.

Gonococcal, uncomplicated infection of the rectumLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, cefixime, in combination with azithromycin, may be used as an alternative agent to ceftriaxone (in combination with azithromycin) for the treatment of uncomplicated gonococcal infections of the rectum only if ceftriaxone is unavailable.

Rhinosinusitis, acute bacterialLevel of Evidence [C, G]

Based on the Infectious Diseases Society of America (IDSA) guidelines for acute bacterial rhinosinusitis (ABRS) in children and adults, cefixime (among other cephalosporins) is effective and recommended alternative agent (in combination with clindamycin) for the treatment of ABRS.

Clinical experience suggests the utility of cefixime (in combination with clindamycin) for the treatment of ABRS ^Ref.

Typhoid feverLevel of Evidence [C]

Clinical experience suggests the utility of cefixime for the treatment of this condition, as an alternative oral agent in the treatment of multidrug-resistant or quinolone-resistant strains ^Ref. However, high failure rates have been reported ^Ref. Additional trials may be necessary to further define the role of cefixime for this condition.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Cephalosporins

Clinical Practice Guidelines

Pneumonia, Community-Acquired:

IDSA/PIDS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age," 2011

Rhinosinusitis:

IDSA, “Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” 2012

Sexually-Transmitted Disease:

CDC, “Sexually Transmitted Diseases Treatment Guidelines,” June 2015.

Public Health Agency of Canada, “Canadian Guidelines on Sexually Transmitted Infections," June 2016

World Health Organization (WHO), "Guidelines for the Treatment of Neisseria gonorrhoeae,” 2016

Administration: Oral

May be administered with or without food. Shake oral suspension well before use. Chewable tablets must be chewed or crushed before swallowing.

Administration: Pediatric

Oral: May be administered with or without food; administer with food to decrease GI distress; shake suspension well before use; chewable tablets must be chewed or crushed before swallowing.

Dietary Considerations

Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).

Storage/Stability

Capsule, chewable tablet: Store at 20°C to 25°C (68°F to 77°F).

Powder for suspension: Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F). After reconstitution, suspension may be stored for 14 days at room temperature or under refrigeration.

Preparation for Administration: Adult

Powder for suspension: Refer to manufacturer’s product labeling for reconstitution instructions.

Preparation for Administration: Pediatric

Oral: Powder for suspension: Reconstitute powder for oral suspension with appropriate amount of water as specified on the bottle. Shake vigorously until suspended.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat bacterial infections.

Frequently reported side effects of this drug

• Nausea

• Vomiting

• Abdominal pain

• Diarrhea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin or eyes

• Kidney problems like not able to pass urine, blood in your urine, change in amount of urine passed, or weight gain

• Chills

• Sore throat

• Bruising

• Bleeding

• Severe loss of strength and energy

• Seizures

• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools.

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

International issues:

Contraindications

Hypersensitivity to cefixime, any component of the formulation, or other cephalosporins or penicillins

Warnings/Precautions

Concerns related to adverse effects:

• Dermatologic reactions: Severe cutaneous reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported. If a reaction occurs, discontinue and institute supportive therapy.

• Hemolytic anemia: Immune-mediated hemolytic anemia (including fatalities) have been reported. Monitor patient (including hematologic parameters and drug-induced antibody testing when clinically appropriate) during and for 2 to 3 weeks after therapy. If hemolytic anemia occurs during therapy, discontinue use.

• Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to cephalosporins, penicillins, or other beta-lactams. If administered to penicillin-sensitive patients, use with caution and discontinue use if allergic reaction occurs.

• Renal failure: May cause acute renal failure including tubulointerstitial nephritis. If renal failure occurs, discontinue and initiate appropriate supportive therapy.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Renal impairment: Use with caution in patients with renal impairment; may increase the risk of seizures if dosage not reduced; modify dosage.

• Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease.

• Hemolytic anemia: Should not be administered to patients with a history of cephalosporin-associated hemolytic anemia; recurrence of hemolysis is more severe.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

• Phenylalanine: Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Adjust dose for renal function.

Warnings: Additional Pediatric Considerations

May cause diarrhea; reported incidence (~16%) similar in children receiving oral suspension and adults receiving tablet dosage form. Use caution when interchanging product formulations; oral suspension and chewable tablets are bioequivalent but oral immediate release tablets are not bioequivalent; for some infections (eg, otitis media), dosing recommendations are product specific.

Pregnancy Considerations

Cefixime crosses the placenta and can be detected in the amniotic fluid (Ozyüncü 2010).

An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics.

Breast-Feeding Considerations

It is not known whether cefixime is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Lexicomp Pregnancy & Lactation, In-Depth

• Cefixime

Briggs' Drugs in Pregnancy & Lactation

• Cefixime

Adverse Reactions

>10%: Gastrointestinal: Diarrhea (16%)

2% to 10%: Gastrointestinal: Abdominal pain, nausea, dyspepsia, flatulence, loose stools

<2%: Acute renal failure, anaphylactoid reaction, anaphylaxis, angioedema, candidiasis, dizziness, drug fever, eosinophilia, erythema multiforme, facial edema, fever, headache, hepatitis, hyperbilirubinemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, jaundice, leukopenia, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness-like reaction, skin rash, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, vomiting

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Cephalosporin Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. Risk C: Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Food Interactions

Food delays cefixime absorption. Management: May administer with or without food.

Test Interactions

Positive direct Coombs', false-positive urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution), may cause false-positive serum or urine creatinine with the alkaline picrate-based Jaffé reaction for measuring creatinine; false-positive urine ketones using tests with nitroprusside (but not those using nitroferricyanide).

Monitoring Parameters

Renal function; with prolonged therapy, monitor renal and hepatic function periodically. Observe for signs and symptoms of anaphylaxis during first dose. When used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC 2012).

Advanced Practitioners Physical Assessment/Monitoring

Assess culture and sensitivity report and patient allergy history prior to starting therapy. Obtain CBC, renal function tests, liver function tests periodically with prolonged therapy. Monitor for signs of anaphylaxis during first dose. Assess for effectiveness of treatment. Test for C.difficile if patient develops diarrhea.

Nursing Physical Assessment/Monitoring

Check lab results and report abnormalities. Monitor closely for signs of hypersensitivity (shortness of breath, dyspnea, chest pain, complaints of difficulty swallowing or throat tightness, or change in vital signs). Monitor for severe or bloody diarrhea and send a specimen to the lab for C.difficile. Monitor for improvement with infection.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Suprax: 400 mg

Generic: 400 mg

Suspension Reconstituted, Oral:

Suprax: 100 mg/5 mL (50 mL) [strawberry flavor]

Suprax: 200 mg/5 mL (50 mL, 75 mL); 500 mg/5 mL (10 mL, 20 mL) [contains sodium benzoate; strawberry flavor]

Generic: 100 mg/5 mL (50 mL); 200 mg/5 mL (50 mL, 75 mL)

Tablet Chewable, Oral:

Suprax: 100 mg, 200 mg [contains aspartame, fd&c red #40 aluminum lake; tutti-frutti flavor]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension Reconstituted, Oral:

Suprax: 100 mg/5 mL (50 mL) [contains sodium benzoate]

Generic: 100 mg/5 mL (50 mL, 100 mL)

Tablet, Oral:

Suprax: 400 mg

Generic: 400 mg

Anatomic Therapeutic Chemical (ATC) Classification

• J01DD08

Generic Available (US)

May be product dependent

Pricing: US

Capsules (Cefixime Oral)

400 mg (per each): $23.52 - $24.91

Capsules (Suprax Oral)

400 mg (per each): $27.68

Chewable (Suprax Oral)

100 mg (per each): $23.44

200 mg (per each): $46.87

Suspension (reconstituted) (Cefixime Oral)

100 mg/5 mL (per mL): $4.45

200 mg/5 mL (per mL): $8.91

Suspension (reconstituted) (Suprax Oral)

100 mg/5 mL (per mL): $5.44

200 mg/5 mL (per mL): $10.89

500 mg/5 mL (per mL): $27.22

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacodynamics/Kinetics

Note: Chewable tablets and oral suspension are bioequivalent. However, oral suspension and capsule formulation are not considered bioequivalent.

Absorption: 40% to 50%; Note: Capsule AUC reduced by ~15% and C_max by ~25% when taken with food.

Distribution: Widely throughout the body and reaches therapeutic concentration in most tissues and body fluids, including synovial, pericardial, pleural, peritoneal; bile, sputum, and urine; bone, myocardium, gallbladder, and skin and soft tissue

Protein binding: 65%

Half-life elimination: Normal renal function: 3 to 4 hours; Moderate impairment (CrCl 20 to 40 mL/minute): 6.4 hours; Renal failure: Up to 11.5 hours

Time to peak, serum: Suspension: 2 to 6 hours; Capsule: 3 to 8 hours; Delayed with food

Excretion: Urine (50% of absorbed dose as active drug); feces (10%)

Pharmacodynamics/Kinetics: Additional Considerations

Geriatric: Average AUCs at steady state in elderly patients are ~40% higher than average AUCs in healthy adults.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Index Terms

Cefixime Trihydrate

FDA Approval Date

April 28, 1989

References

“1998 Guidelines for the Treatment of Sexually Transmitted Diseases. Centers for Disease Control and Prevention,” MMWR Recomm Rep, 1998, 47(RR-1):1-111.

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.

American Academy of Pediatrics Subcommittee on Urinary Tract Infection. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610.[PubMed 21873693]

Ashkenazi S, Amir J, Waisman Y, et al, “A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis,” J Pediatr, 1993, 123(5):817-21.[PubMed 8229498]

Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, Clin Infect Dis, 2011, 53(7):e25-76.[PubMed 21880587]

Cao XT, Kneen R, Nguyen TA, et al, "A Comparative Study of Ofloxacin and Cefixime for Treatment of Typhoid Fever in Children. The Dong Nai Pediatric Center Typhoid Study Group," Pediatr Infect Dis J, 1999, 18(3):245-8.[PubMed 10093945]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Centers for Disease Control and Prevention (CDC), "Sexually Transmitted Diseases Treatment Guidelines, 2010," MMWR Recomm Rep, 2010, 59(RR-12):1-110.[PubMed 21160459]

Centers for Disease Control and Prevention (CDC), "Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections”, MMWR Morb Mortal Wkly Rep, 2012, 61(31):590-4.[PubMed 22874837]

Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” Clin Infect Dis, 2012, 54(8):e72-112.[PubMed 22438350]

Daschner M. Drug dosage in children with reduced renal function. Pediatr Nephrol. 2005;20:1675-1686.[PubMed 16133064]

Dhib M, Moulin B, Leroy A, et al. Relationship between renal function and disposition of oral cefixime. Eur J Clin Pharmacol. 1991;41:579-583.[PubMed 1815970]

Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500.[PubMed 3277054]

Faulkner RD, Bohaycheck W, Lanc RA, et al, “Pharmacokinetic of Cefixime in Young and Elderly,” J Antimicrob Chemother, 1988, 21(6):787-94.[PubMed 3410802]

Girgis NI, Sultan Y, Hammad O, et al, "Comparison of the Efficacy, Safety and Cost of Cefixime, Ceftriaxone and Aztreonam in the Treatment of Multidrug-Resistant Salmonella typhi Septicemia in Children," Pediatr Infect Dis J, 1995, 14(7):603-5.[PubMed 7567290]

Guay DRP, Meatherall RC, Harding GK, et al. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 1986;30(3):485-490.[PubMed 3777912]

Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120.[PubMed 21292654]

Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. doi: 10.7326/M15-1840.[PubMed 26785402]

Hooton TM, Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Available at http://www.uptodate.com. Accessed April 19, 2018.

Hooton TM, Gupta K. Acute uncomplicated cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Available at http://www.uptodate.com. Accessed May 3, 2018.

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Johnson CE, Carlin SA, Super DM, et al, “Cefixime Compared With Amoxicillin for Treatment of Acute Otitis Media,” J Pediatr, 1991, 119(1):117-22.[PubMed 1906097]

Johnson JR, Russo TA. Acute pyelonephritis in adults. N Engl J Med. 2018;378(1):48-59.[PubMed 29298155]

Klaassen RJ, Allen U, and Doyle JJ, "Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and Neutropenia," J Pediatr Hematol Oncol, 2000, 22(5):405-11.[PubMed 11037850]

Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082-2094.[PubMed 28459614]

Levine WC, Berg AO, Johnson RE, et al, “Development of Sexually Transmitted Diseases Treatment Guidelines, 1993. New Methods, Recommendations, and Research Priorities,” STD Treatment Guidelines Project Team and Consultants, Sex Transm Dis, 1994, 21(2 Suppl):96-101.

Markham A and Brogden RN, “Cefixime. A Review of Its Therapeutic Efficacy in Lower Respiratory Tract Infections,” Drugs, 1995, 49(6):1007-22.[PubMed 7641600]

Marshall WF and Blair JE, “The Cephalosporins,” Mayo Clin Proc, 1999, 74(2):187-95.[PubMed 10069359]

Moustafa F, Nguyen G, Mathevon T, et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother. 2016;71(6):1660-1664.[PubMed 26903277]

Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008;35(1):1-12.[PubMed 18061019]

Ozyüncü O, Beksac MS, Nemutlu E, et al, "Maternal Blood and Amniotic Fluid Levels of Moxifloxacin, Levofloxacin and Cefixime," J Obstet Gynaecol Res, 2010, 36(3):484-7.[PubMed 20598025]

Paganini HR, Sarkis CM, De Martino MG, et al, "Oral Administration of Cefixime to Lower Risk Febrile Neutropenic Children With Cancer," Cancer, 2000, 88(12):2848-52.[PubMed 10870071]

Pandit A, Arjyal A, Day JN, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One. 2007;2(6):e542.[PubMed 17593957]

Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347(22):1770-82.[PubMed 12456854]

Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 24, 2018.

Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Available at http://www.uptodate.com. Accessed November 6, 2018.

Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html. Accessed August 8, 2017.

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39. doi: 10.1177/0194599815572097.[PubMed 25832968]

Sanchez M, Collvinent B, Miró O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002;19(1):19-22.[PubMed 11777865]

Schatz BS, Karavokiros KT, Taeubel MA, et al, “Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten,” Ann Pharmacother, 1996, 30(3):258-68.[PubMed 8833562]

Shenep JL, Flynn PM, Baker DK, et al, "Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children With Cancer," Clin Infect Dis, 2001, 32(1):36-43.[PubMed 11112678]

Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102. doi: 10.1093/cid/cis629.[PubMed 22965026]

Smith GH, “Oral Cephalosporins in Perspective,” DICP, 1990, 24(1):45-51.[PubMed 2405586]

Stephens I and Levine MM, "Management of Typhoid Fever in Children," Pediatr Infect Dis J, 2002, 21(2):157-8.[PubMed 11840084]

Suprax (cefixime) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; October 2019.

Suprax (cefixime) [product monograph]. Pointe-Claire, Quebec, Canada: Odan Laboratories; April 2018.

Wagner LM, Crews KR, Stewart CF, et al, "Reducing Irinotecan-Associated Diarrhea in Children," Pediatr Blood Cancer, 2008, 50(2):201-7.[PubMed 17570704]

Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.[PubMed 26042815]

World Health Organization (WHO), “Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever,” May 2003. Available at http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf

Brand Names: International

Aerocef (AT, EG); Anfix (ID); Cavlis (CR, DO, GT, HN, NI, PA, SV); Cefarox (ID); Cefexin (HR); Cefiac (BD); Cefiget (VN); Cefim (BD, BH, ET, KW); Cefimark (VN); Cefime (EG); Cefimed (ET); Cefirax (KR); Cefix (AE, BH, CY, ET, IQ, IR, JO, KR, KW, LB, LY, MY, OM, SA, SY, YE); Cefixmycin (PH, TW); Ceforal (UA); Cefrax (BH); Cefspan (CN, ID, JP, PK, TH, TW, VN); Ceftoral (GR); Celix (UA); Cephoral (CH, DE); Cerafix (ID); Cexim (TW); Cexima (PY); Chifix (LK); Cifacure (PH); Cifex (TR); Denvar (CR, DO, ES, GT, HN, MX, NI, PA, SV); Devoxim (CO); Edixim (HR); Eficef (RO); Fix A (BD); Fix-A (PH); Fixcef (PH); Fixef (ID); Fixim (CR, DO, GT, HN, LB, NI, NL, PA, SV); Fixime (ZA); Fixitil-T (LK); Fixx (IN); Hafixim (VN); Innoxime (ZW); Ixime (AE, MY, PH, UA); Lanfix (ID); Longacef (VE); Loprax (UA); Magnacef (AE, BH, JO, LB, QA, SA); Maxicef (PE); Maxpro (ID); Minixime (MY); Mycefix (PH); Neocef (PT); Nixaven (ID); Novacef (AR); Oralcef (PY); Oroken (FR); Pancef (BG); Profim (ID); Refix (PH); Sanfix (PH); Savecef (LK); Septipan (PH); Simfix (ID); Sixime (TH); Sofix (ID); Spaxim (ID); Starcef (ID); Supracef (FI); Supran (IL); Suprax (AE, BB, BH, CZ, DE, EG, GB, HU, IE, IT, JO, KR, KW, LB, QA, RU, SA, SK, TR); Surixime (PH); Tadix (CR, DO, GT, HN, NI, PA, SV); Taxocef-O (PH); Tergecef (PH); Tocef (ID); Topcef (LK); Tricef (BD, CL, MT, PT, SE, TR); Ultraxime (PH); Vamocef (PH); Vipime (LK); Winex (AE, BH, KW, LB, QA, SA); Xifia (RO); Ximacef (EG); Ximecef (ID); Ximeceff (IN); Yafix (ID); Z-Fix (PH); Zefral (PH); Zifi (MY)

Last Updated 3/11/20